Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Defence Therapeutics ( (TSE:DTC) ) has provided an update.
Defence Therapeutics announced its participation in the Biotech Showcase during the J.P. Morgan Healthcare Conference in San Francisco, aiming to connect with industry leaders and potential partners. The company has closed the first tranche of its non-brokered private placement, raising $300,000 to fund preclinical and clinical programs, illustrating its strategic efforts to enhance its market presence and technological advancements.
More about Defence Therapeutics
Defence Therapeutics Inc. is a Canadian biopharmaceutical company that focuses on developing radiopharmaceuticals and antibody-drug conjugates (ADCs) using its proprietary platform and drug delivery technologies. The company also works on novel immune-oncology vaccines and is publicly traded as a clinical-stage biotechnology firm.
YTD Price Performance: 15.38%
Average Trading Volume: 1,535
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.96M
See more data about DTC stock on TipRanks’ Stock Analysis page.
